American Financial Group, Inc. (AFG)

Verve Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-	887	852	898	1,995	732
Depreciation & Amortization	-	81	78	100	187	299
Gain (Loss) on Sale of Assets	-	-	2	-6	-1,021	-388
Gain (Loss) on Sale of Investments	-	-	36	116	-110	75
Reinsurance Recoverable	-	-769	-794	-644	-350	-533
Change in Insurance Reserves / Liabilities	-	1,225	1,318	1,105	912	812
Change in Other Net Operating Assets	-	-223	358	-390	130	92
Other Operating Activities	-	-54	-31	-141	-142	1,081
Operating Cash Flow	-	1,152	1,970	1,153	1,714	2,183
Operating Cash Flow Growth	-	-41.52%	70.86%	-32.73%	-21.48%	-11.12%
Cash Acquisitions	-	-9	-208	-10	-2,181	-428
Investment in Securities	-	609	813	-686	-1,911	-886
Other Investing Activities	-	-252	-156	-145	225	90
Investing Cash Flow	-	95	414	-1,051	-436	-1,564
Long-Term Debt Issued	-	-	-	-	-	634
Total Debt Repaid	-	-	-21	-477	-	-150
Net Debt Issued (Repaid)	-	-	-21	-477	-	484
Issuance of Common Stock	-	17	15	16	66	22
Repurchases of Common Stock	-	-	-213	-11	-319	-313
Common Dividends Paid	-	-243	-218	-193	-164	-161
Other Financing Activities	-	-295	-1,128	324	227	282
Financing Cash Flow	-	-1,066	-2,031	-1,361	-1,957	-123
Net Cash Flow	-	181	353	-1,259	-679	496
Cash Interest Paid	-	74	74	89	92	83
Cash Income Tax Paid	-	201	201	242	212	179
Levered Free Cash Flow	-	170.25	141.88	498.5	4,319	-4,720
Unlevered Free Cash Flow	-	232.75	205.63	551.63	4,378	-4,665
Change in Net Working Capital	-	640	636	328	-3,262	5,571

Updated May 8, 2025. Source: S&P Global Market Intelligence. Insurance template. Financial Sources.

SEC Filings: 10-K · 10-Q